Results 41 to 50 of about 311 (111)
Journal of Internal Medicine, Volume 300, Issue 6, Page 725-742, December 2026.Abstract Lipodystrophy comprises a heterogeneous group of disorders characterized by reduced adipose tissue often associated with severe metabolic complications. Lipodystrophy may be genetic, acquired, or secondary to medical therapies initiated for other conditions.
Robert K. Semple +25 more
wiley +1 more source
Journal of the Endocrine Society, 2023 Abstract Disclosure: Z. Zadik: None. N. Zelinska: Consulting Fee; Self; Novo Nordisk, Berlin-Chemie, Medtronic, Sanofi-Aventis. Research Investigator; Self; MacroGenics, Novo Nordisk, Pfizer, Inc., Merck, OPKO Health, Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Parexel, Genexine. Speaker; Self; Medtronic, Berlin-Chemie,
Zadik, Zvi +14 more
openaire +1 more source
Drug Testing and Analysis, Volume 18, Issue 4, Page 458-482, April 2026.New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley +1 more source
Drug Testing and Analysis, Volume 17, Issue 8, Page 1417-1442, August 2025.Scenarios of drug exposure and administration as well as detection assays for drugs and methods of sports doping published between 2023 and 2024 are critically reviewed and evaluated in context with the Prohibited List 2024 as established by the World Anti‐Doping Agency.
Mario Thevis +2 more
wiley +1 more source
Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
ChemBioChem, Volume 25, Issue 8, April 16, 2024.Peptide nanostructures with tunable structural features, multifunctionality, biocompatibility and biomolecular recognition capacity enable development of targeted drug delivery tools for precision medicine applications. In this review article, we present various techniques employed for the synthesis and self‐assembly of peptides into nanostructures ...
HaRam Kim +4 more
wiley +1 more source
Drug Design, Development and Therapy, 2022 Bradley S Miller,1 Kevin CJ Yuen2 1Pediatric Endocrinology, University of Minnesota Medical School, Minneapolis, MN, USA; 2Department of Neuroendocrinology and Neurology, Barrow Pituitary Center, University of Arizona College of Medicine and Creighton ...
Miller BS, Yuen KCJ
doaj
Background: The first Long-Acting Growth Hormone (LAGH) therapy, Somatrogon, has been available in Italy since March 2023 for children with growth hormone deficiency (GHD) older than 3 years, offering a convenient way of administering the treatment once ...
Gianluca Tamaro +3 more
core +1 more source
Drug utilization of specific biotherapeutic agents and biosimilars in the Czech Republic [PDF]
, 2023 Drug utilization of specific biotherapeutic agents and biosimilars in the Czech Republic Author: Olha Vasko Supervisor: PharmDr. Simona Dvořáčková, Ph.D. Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Králové, Charles University
Vasko, Olha
core
, 2022 This is a plain language summary (PLS) of an article published in a peer-reviewed scientific journal. This PLS is not peer-reviewed. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor ...
Mauri Carakushansky (5120351) +11 more
core +1 more source
Lipoatrophy following weekly growth hormone therapy: a case report
Objectives: Traditional daily recombinant human growth hormone injections can be burdensome for patients and caregivers, leading to compliance issues. Long-acting growth hormone formulations have been developed to overcome these challenges.
Bas, Veysel Nijat, Hazer, İLHAN
core +1 more source